Additive Effects of Alternative Nostril Breathing with Pharmacological Management on Dyspnea and Control Pause in Patients with Bronchial Asthma

NCT06609941 | Recruiting

• 1 other identifier: FUI/CTR/2024/25
• Study Type: interventional
• Target: 32
• Locations: 1 country
• Sites: 1

Brief Summary

Bronchial asthma is a widespread chronic condition charactrized by inflammation and narrowing of airways, leading to repeateted episodes of breathlessness, wheezing and labored breathing.Breathing exercises help to manage hyperventilation often seen in asthmatic patients. To handle respiratory complications asthmatics are advised to practise nasal breathing techniques in conjunction with their prescribed medications.

Conditions

Bronchial Asthma

Keywords

Dyspnea, asthma control, peak expiratory flow rate

Outcome Measures

Primary Outcomes (4)

• Dyspnea

  Evaluation will be done using Dyspnea-12 questionnaire for dyspnea

  4 weeks

• Control pause

  Stopwatch will be used to measure control pause.

  4 weeks

• Asthma control

  Asthma control test (ACT) will be used to evaluate asthma control and peak flow meter for peak expiratory flow rate.

  4 weeks

• Peak expiratory flow rate.

  Peak flow meter will be used to measure peak expiratory flow rate

  4 Weeks

Study Arms (2)

Nostril Breathing along with pharmacological therapy Group

EXPERIMENTAL

Patients in this group will receive alternative nostril breathing along with pharmacological management. Total 4 weeks protocol. Two sessions per week will be supervised by physiotherapist and 5 days at home. A home diary will be provided in order to ensure and follow-up that participants are performing breathing exercise at home.

Other: Alternative nostril breathing; Drug: Pharmacological therapy

Pharmacological therapy Group

ACTIVE COMPARATOR

Patients will receive medication as prescribed by pulmonologist through stepwise approach according to symptoms and severity. Total 4 weeks protocol. Before and after 4 weeks pre and post interventional values will be taken.

Drug: Pharmacological therapy

Interventions

Alternative nostril breathing OTHER

Patients in this group will receive alternative nostril breathing along with pharmacological management. For alternative nostirl breathing patient will be advised to inhale slowly (4sec) and deeply through left nostril.Then hold breath for 2-3 sec. Release right nostril and use right ring finger to close left nostril. Exhale slowly (6sec) and completely through right nostril. Inhale slowly (4sec) and deeply through right nostril. Then hold breath for 2-3sec. Release left nostril and use right thumb to close right nostril. Exhale slowly (6sec) and completely through left nostril. Repeat the cycle.

Nostril Breathing along with pharmacological therapy Group

Pharmacological therapy DRUG

Participants in this group will only be provided with standard pharmacological management for 4 weeks as prescribed by a pulmonologist. For example: Salbutamol inhaler (Short acting bronchodilator) Saltra inhaler (Selective long acting β2 adrenoceptor agonist) Tiotropium (Anticholinergic) Combivir (Nucleoside analogue - reverse transcriptase inhibitor) etc. Week 01 and week 02: Patients will receive medication prescribed by pulmonologist. Week 03 and week 04: Patients will receive medication prescribed by pulmonologist.

Nostril Breathing along with pharmacological therapy Group; Pharmacological therapy Group

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Adults: aged (18-45 years)
• Gender: Both males and females
• Grade1- Grade 4 on Modified MRC dyspnea scale
• Asthma severity classes (intermediate, mild persistent and moderate persistent asthma) acc. to NAEPP national asthma education and prevention program guidlin

You may not qualify if:

• Patients having acute exacerbation of COPD or status asthmaticus
• Patients diagnosed with acute infections
• Patients unable to follow command/ instructions
• Asthma patients with \>40 sec control pause duration
• Patients who fall in red zone of asthma action plan (PEFR \< 50%)

Sponsors & Collaborators

• Foundation University Islamabad: lead

Study Sites (1)

Foundation University College of Physical Therapy

Rawalpindi, Punjab Province, 46000, Pakistan

RECRUITING

MeSH Terms

Conditions

Asthma; Dyspnea

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Respiration Disorders; Signs and Symptoms, Respiratory; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Bazkha Tariq Aslam Khawaja, DPT

CONTACT

0333-1281293; bazkhatariq@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: This is a randomized controlled trial having two groups. One group will receive (interventional group) alternative nostril breathing along with pharmacological management and the other group (control group) will receive only pharmacological management.

Study Record Dates

• First Submitted: September 20, 2024
• First Posted: September 24, 2024
• Study Start: June 18, 2024
• Primary Completion: January 1, 2025
• Study Completion: February 1, 2025
• Last Updated: September 24, 2024

Record last verified: 2024-08

Locations

PA (1)